Aggensteiner, Pascal-M.
Böttinger, Boris
Baumeister, Sarah
Hohmann, Sarah
Heintz, Stefan
Kaiser, Anna
Häge, Alexander
Werhahn, Julia
Hofstetter, Christoph
Walitza, Susanne
Franke, Barbara
Buitelaar, Jan
Banaschewski, Tobias
Brandeis, Daniel
Holz, Nathalie E.
Funding for this research was provided by:
European Union’s Seventh Framework Programme for research, technological development, and demonstration (602805, 602805, 602805, 602805, 602805, 602805, 602805, 602805, 602805, 602805, 602805)
Article History
Received: 17 May 2023
Accepted: 21 December 2023
First Online: 8 February 2024
Declarations
:
: TB served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Lundbeck, Medice, Novartis and Shire. He received conference support or speaker’s fees from Lilly, Medice, Novartis and Shire. He has been involved in clinical trials conducted by Shire and Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP Medien and Oxford University Press. SW has received in the last 5 years royalties from Thieme, Hogrefe, Kohlhammer, Springer, Beltz. In 2023 she received speakers honorary from Takeda and Medice. DB served as an unpaid scientific advisor for an EU-funded neurofeedback trial unrelated to the present work. BF received educational speaking fees from Shire and Medicin. All other authors declare no competing interests.